bpc 157 doctor near me BPC-157 in Raleigh, NC SynaPep™ BPC-157 Treatment | Podiatrist,

Get help managing your appointment We recommend scheduling your appointment ahead of time to guarantee availabilityespecially for popular treatments

Semaglutide therapy is initiated at a low dose, and the dose is increased gradually to allow the body to adjust to the medication

**AOD-9604 clinical data:** - One Phase 2b clinical trial was conducted in approximately 300 obese adults in Australia - Results showed **no statistically significant difference** in weight loss between AOD-9604 and placebo groups - The trial was considered a failure, and Metabolic Pharmaceuticals did not advance AOD-9604 to Phase 3 - Total clinical weight loss data in humans: fewer than 500 participants across all studies - Typical AOD-9604 results reported anecdotally: 1-3 kg over several months **Semaglutide clinical data:** - The STEP clinical trial program included over **4,500 participants** across multiple Phase 3 trials - STEP 1 demonstrated **14.9% mean body weight loss** (vs 2.4% placebo) over 68 weeks - STEP 5 confirmed weight loss maintenance of approximately **15.2%** over two full years - STEP 4 showed that discontinuing semaglutide leads to weight regain, confirming its active role in fat loss - The SELECT trial (17,604 participants) demonstrated a **20% reduction in major cardiovascular events** - Total clinical participants: over 20,000 across all weight loss and cardiovascular trials | Metric | AOD-9604 | Semaglutide | |--------|----------|-------------| | Phase 3 weight loss trial | Failed / not completed | Multiple successful trials | | Mean weight loss (%) | Not statistically significant vs placebo | 14.9-16.9% body weight | | Total clinical participants | ~500 | 20,000+ | | FDA approval for weight loss | No | Yes (Wegovy) | | Cardiovascular outcomes data | None | Yes (SELECT trial 20% MACE reduction) | | Long-term data (2+ years) | None | Yes (STEP 5) | | Published in top journals | Limited | NEJM, JAMA, Lancet, Nature Medicine | ### Safety and Side Effects **AOD-9604 side effects:** - Generally well-tolerated in limited studies - Injection site reactions - Headache (infrequent) - No significant GI side effects - **Critical caveat:** The absence of side effects partly reflects the lack of robust biological activity in humans **Semaglutide side effects:** - Nausea (most common, typically transient resolves with dose titration) - Vomiting, diarrhea, constipation - Injection site reactions - Rare reports of pancreatitis - Well-characterized safety profile from extensive clinical trials - Most GI side effects can be managed with proper [dose titration](/guides/semaglutide-dosing-schedule-week-by-week-guide) For guidance on proper **peptide injection** technique to minimize discomfort, see our [GLP-1 injection guide](/guides/how-to-inject-glp1-medications-guide)

Lambs 0.5mL at tailing or weaning Sheep1 - 1.5mL pre-lambing Calves 2 - 3mL from 2 months of age Cows 4 - 6mL pre-calving DO NOT dose within 3 months of the previous dose Do Not exceed stated dose Cobalt deficiency in soil and/or pasture leads to a lack of Vitamin B12 in body tissues of stock which, subsequently, may have poor growth rates and ill thrift, particularly in young animals Before treatment, establish selenium status of stock, pasture cobalt levels and/or Vitamin B12 status of stock Do not use this product unless animals are deficient in both cobalt and selenium Treatment is likely to last only 4-6 weeks if liver storage levels of Vitamin B12 and pasture levels of cobalt are low Treatment of pregnant ruminants should benefit newborn animals, particularly when treated in latter stages of pregnancy Supplementation of young ruminants should begin at or before weaning Do not redose with this product within three months of the previous dose